Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why AbbVie's Stock Sank in the First Half of 2019

By George Budwell - Jul 4, 2019 at 12:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie's stock has been hit hard by Humira's loss of exclusivity in Europe and the biotech's megamerger with Allergan.

What happened

Biopharma giant AbbVie ( ABBV 2.10% ) has had an absolutely regrettable year. Through the course of the first six months of the year, the drugmaker's shares have lost a breathtaking 21.2% of their value, according to data from S&P Global Market Intelligence.

Why did investors give AbbVie's stock the cold shoulder in the first half of 2019? Two reasons. First off, the company's flagship arthritis medication Humira saw its European sales take a big hit following the introduction of biosimilar competition. Second, AbbVie decided to address Humira's patent cliff by acquiring Botox maker Allergan ( AGN ) for a whopping $63 billion.

A man with a laptop folded over his head, holding a sign that reads "help!"

Image Source: Getty Images.

So what

AbbVie's massive drop-off this year might be a blessing in disguise. After all, the company's shares are now trading at less than eight times next year's projected earnings, and its dividend yield has ballooned to a sky-high 5.77% in response to this double-digit downturn.

Topping it off, AbbVie also grabbed an FDA approval for its next-generation immunology drug Skyrizi earlier this year. While Skyrizi won't be a panacea for AbbVie's patent woes, it should at least help to blunt the impact of Humira's ongoing battle with biosimilars. Stated simply, AbbVie's stock might have fallen too far too fast in 2019.

Now what

Is AbbVie a bargain? The answer to this question ultimately depends on how this megamerger with Allergan pans out. Wall Street wasn't initially sold on the deal due to the lack of any clear-cut synergies between the two companies and the fact that Allergan has been dealing with its own patent problems of late.

However, this tie-up does dilute Humira's overall importance from a revenue generation standpoint, and that's a big positive. AbbVie, in turn, might turn out to be an outstanding bargain if management can somehow mesh together two drastically different product portfolios while also maintaining the company's status as a Dividend Aristocrat in the years to come. That's a tall order based on how things stand now, but it's not an impossible feat, either.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$121.35 (2.10%) $2.50
Allergan plc Stock Quote
Allergan plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.